Imagine trying to understand a crowd by only looking at the average height of everyone; you miss the one giant or the one tiny person. This technology puts individual cells into tiny droplets, like miniature test tubes, so scientists can see exactly what each cell is doing. It allows them to pick the 'superstar' cells that kill cancer most effectively without the noise of a crowd.
Drug development is slowed by bulk cell analysis that hides biological differences between cells. This leads to insufficient data and a failure to identify the most potent cells for therapy.
The Xdrop Plus platform and the Xplore all-in-one analyzer/sorter, which encapsulate cells in droplets for functional analysis.
If you are a drug developer dealing with slow screening of antibody-producing cells — this project developed Xdrop Plus that allows millions of cells to be screened to identify those with the desired functionality.
If you are a therapy provider dealing with the inability to see individual cell potency in bulk populations — this project developed Xplore that enables screening and selection of immune cells based on their actual killing potential.
If you are a manufacturer dealing with expensive chemical processes — this project developed a platform for enzyme engineering to replace those chemicals with sustainable biological solutions.
Based on available project data, the platform is described as a cost-effective solution that uses standard laboratory instruments to keep the technology accessible, though specific pricing is not listed.
Yes, the platform is designed for high-throughput screening, capable of analyzing millions of antibody-producing cells.
Based on available project data, the technology is developed by Samplix ApS, but specific licensing terms are not provided.
The system is designed to prepare single cells for analysis on standard laboratory instruments, making it compatible with current cell and immune therapy research workflows.
The project period is from 2023-08-01 to 2025-07-31.
The project is led by a single SME, Samplix ApS from Denmark, which holds 100% of the industry ratio. This lean structure suggests a focused commercial drive to bring the Xdrop Plus and Xplore products to market without the complexity of a large academic consortium.
Contact Samplix ApS in Denmark for partnership opportunities regarding Xdrop Plus.
Contact us to explore how single-cell resolution can accelerate your drug discovery pipeline.
